{"product_id":"healius-swot-analysis","title":"Healius SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMake Insightful Decisions Backed by Expert Research\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eHealius shows resilient healthcare revenue streams, strong diagnostic capabilities, and strategic partnerships, but faces margin pressure, regulatory risks, and competitive headwinds; our concise SWOT highlights the essentials. Purchase the full SWOT analysis to access a research-backed, editable Word and Excel package with detailed insights, financial context, and strategic recommendations for investors and advisors.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDominant Pathology Market Share\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHealius ranks as one of Australia’s top two pathology providers, operating brands Laverty and QML and processing roughly 18–20 million tests annually by end-2025, securing scale advantages. This volume spreads high fixed costs—labs, equipment—keeping unit costs lower and supporting margins in a price-sensitive market. Its ~550 collection centres nationwide remain a primary gateway for diagnostic data, feeding clinical and hospital networks and generating predictable referral flows.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Lumus Imaging Network\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Lumus Imaging division is a high-value asset in Healius’ portfolio, generating roughly A$380m revenue in FY2024 and covering services from X-ray to 3T MRI, PET-CT and interventional imaging.\u003c\/p\u003e\n\u003cp\u003eIt draws referrals from a diversified mix—55% hospital-contracted work and 45% community sites—reducing single-source dependency and smoothing volumes.\u003c\/p\u003e\n\u003cp\u003eHigh-end kit and premium imaging margins (estimated EBITDA margin ~22% in 2024) give a defensive revenue stream that offsets pathology’s cyclicality and lowers overall group volatility.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExtensive Geographic Footprint\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHealius operates over 350 pathology collection centres and more than 200 diagnostic imaging sites across urban and regional Australia, giving broad patient access and 40% market share in several states as of FY2024. This footprint costs new entrants hundreds of millions in capex and complex licensing, creating high barriers to entry. Governments and CROs prefer Healius for large-scale programs—Healius ran multiple state screening contracts and supported 12 clinical trial networks in 2024. The scale boosts referral volumes and revenue resilience, with FY2024 group revenue ~A$1.2bn.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced Diagnostic Capabilities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHealius has invested in high-throughput lab automation and genomics\/molecular diagnostics, growing its complex-test volume to support higher-margin services; in FY2024 the pathology division reported a 6.2% EBITDA margin improvement linked to advanced testing adoption.\u003c\/p\u003e\n\u003cp\u003eThese high-complexity tests, now ~18% of pathology revenue, are vital for oncology and personalized medicine, so Healius acts as a clinical decision partner for specialists and referral networks.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh-throughput automation deployed across 12 labs\u003c\/li\u003e\n\u003cli\u003eGenomics\/molecular = ~18% of pathology revenue (FY2024)\u003c\/li\u003e\n\u003cli\u003eEBITDA margin +6.2% in pathology (FY2024)\u003c\/li\u003e\n\u003cli\u003eFocus on oncology\/personalized medicine referrals\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEstablished Brand Equity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHealius, via subsidiaries like Primary Health Care and Sonic Healthcare partnerships, holds decades-long ties with GPs and specialists nationwide, driving steady referrals; FY2024 Australian pathology revenue contribution was ~45%, supporting market resilience.\u003c\/p\u003e\n\u003cp\u003eThis brand recognition—linked to perceived clinical excellence—boosts patient loyalty and creates a moat that limits market share erosion by smaller independents; Sonic\/Healius combined footprint served ~25% of outpatient diagnostics in 2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDecades of GP\/specialist relationships\u003c\/li\u003e\n\u003cli\u003e~45% of group revenue from pathology (FY2024)\u003c\/li\u003e\n\u003cli\u003e~25% share of outpatient diagnostics (2024)\u003c\/li\u003e\n\u003cli\u003eHigh patient loyalty, steady referral flow\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealius: A$1.2bn healthcare leader—18–20M tests, Lumus A$380m, strong imaging margins\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHealius is a top-2 Australian pathology provider (18–20M tests p.a. by end-2025), ~350 collection centres, \u0026gt;200 imaging sites; FY2024 group revenue ~A$1.2bn, Lumus Imaging ~A$380m, pathology ~45% revenue, genomics ~18% of pathology, pathology EBITDA margin +6.2pp (FY2024), imaging EBITDA ~22% (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTests p.a.\u003c\/td\u003e\n\u003ctd\u003e18–20M (end‑2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGroup revenue\u003c\/td\u003e\n\u003ctd\u003eA$1.2bn (FY2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLumus Imaging\u003c\/td\u003e\n\u003ctd\u003eA$380m (FY2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGenomics\u003c\/td\u003e\n\u003ctd\u003e18% pathology rev (FY2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a concise SWOT overview of Healius, highlighting its core strengths, operational weaknesses, market opportunities, and external threats shaping strategic decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise Healius SWOT matrix for fast, visual strategy alignment, helping executives quickly spot clinical, regulatory, and market risks while highlighting growth opportunities.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eElevated Operational Gearing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHealius carries elevated operational gearing with fixed costs—A$420m in FY2024 property, plant and equipment and ~60% of cost base fixed—driven by lab leases and a 380-site collection network; small volume swings (volumes fell ~8% YoY in 2023–24) therefore hit EBIT disproportionately. Managing overheads is hard now that post‑pandemic testing volumes have normalised and margin sensitivity to volume remains high.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHistorical Margin Underperformance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCompared with primary peer Sonic Healthcare, Healius reported a FY2024 EBIT margin of ~8.2% versus Sonic’s ~12.5%, reflecting persistent underperformance tied to less efficient international diversification and higher corporate costs.\u003c\/p\u003e\n\u003cp\u003eManagement cut costs and exited non-core assets in 2023–2025, lifting pro forma EBIT margin to ~9.6% in H1 FY2025, but Healius still must prove it can sustain top-quartile efficiency.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Debt-to-Equity Ratio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cpdespite divestments healius reported net debt of a at sep keeping its debt-to-equity around and showing persistent leverage. high mid-2020s interest rates lifted finance costs to in fy2024 squeezing free cash flow reducing funds for expansion or it upgrades. investors worry the group may need dilutive equity fund growth given constrained headroom covenant pressures.\u003e\n\u003c\/pdespite\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReliance on Medicare Funding\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpa substantial portion of healius revenue in fy2024 from the medicare benefits schedule so changes to government rebates or indexing shortfalls directly cut profit margins and ebitda.\u003e\n\u003cpthe company faces political risk beyond management control: the real rebate freeze and cumulative medicare indexation below cpi raised per-test cost pressures squeezed margins in pathology imaging segments.\u003e\n\u003cp class=\"lst_crct\"\u003e\n\u003c\/p\u003e\u003cli\u003e~30% revenue from Medicare (FY2024)\u003c\/li\u003e\n\u003cli\u003eMedicare indexation lagged CPI by ~2% (2019–2024)\u003c\/li\u003e\n\u003cli\u003eRebate policy changes can cut margins immediately\u003c\/li\u003e\n\n\u003c\/pthe\u003e\u003c\/pa\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePast Corporate Governance Instability\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eHealius endured multi-year boardroom tension—leadership turnover and failed takeover bids in 2022–2024—that diverted focus from operations and coincided with a 18% share-price underperformance vs the ASX200 through 2023.\u003c\/p\u003e\n\u003cp\u003eBy late 2025 the board is more settled, but legacy conflicts still raise its risk premium: implied equity risk premium in Jan 2025 was ~2.1ppt above peers, per market pricing.\u003c\/p\u003e\n\u003cp class=\"lst_crct\"\u003e\u003c\/p\u003e\n\u003cli\u003eBoard turnover 2022–24; failed bids by competitors\u003c\/li\u003e\n\u003cli\u003e18% cumulative underperformance vs ASX200 to end‑2023\u003c\/li\u003e\n\u003cli\u003e~2.1ppt higher implied risk premium in Jan 2025\u003c\/li\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealius: high leverage, weak volumes dent margins; rising debt and governance risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHealius shows high operating leverage (A$420m PPE FY2024; ~60% fixed costs), so an ~8% volume fall in 2023–24 cut EBIT sharply; FY2024 EBIT margin ~8.2% vs Sonic 12.5%. Net debt A$700m (30 Sep 2024), debt\/equity ~1.1x, finance costs A$55m FY2024; ~30% revenue from Medicare (indexation ~2% below CPI 2019–24). Board turnover 2022–24 raised implied risk premium ~2.1ppt (Jan 2025).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePPE FY2024\u003c\/td\u003e\n\u003ctd\u003eA$420m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFixed cost share\u003c\/td\u003e\n\u003ctd\u003e~60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVolume change 2023–24\u003c\/td\u003e\n\u003ctd\u003e-8%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEBIT margin FY2024\u003c\/td\u003e\n\u003ctd\u003e~8.2%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSonic EBIT margin\u003c\/td\u003e\n\u003ctd\u003e~12.5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet debt (30 Sep 2024)\u003c\/td\u003e\n\u003ctd\u003eA$700m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDebt\/equity\u003c\/td\u003e\n\u003ctd\u003e~1.1x\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinance costs FY2024\u003c\/td\u003e\n\u003ctd\u003eA$55m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedicare revenue share FY2024\u003c\/td\u003e\n\u003ctd\u003e~30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedicare indexation gap 2019–24\u003c\/td\u003e\n\u003ctd\u003e~2% vs CPI\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImplied risk premium (Jan 2025)\u003c\/td\u003e\n\u003ctd\u003e~+2.1ppt vs peers\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eSame Document Delivered\u003c\/span\u003e\u003cbr\u003eHealius SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual Healius SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality.\u003c\/p\u003e\n\u003cp\u003eThe preview below is taken directly from the full SWOT report you'll get; purchase unlocks the complete, editable version with in-depth insights and structured findings.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56752431104377,"sku":"healius-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/healius-swot-analysis.png?v=1772240911","url":"https:\/\/matrixbcg.com\/products\/healius-swot-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}